Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment

Abstract Background Despite the efficacy of immune checkpoint inhibitors (ICIs) only the 20–30% of treated patients present long term benefits. The metabolic changes occurring in the gut microbiota metabolome are herein proposed as a factor potentially influencing the response to immunotherapy. Meth...

Full description

Bibliographic Details
Main Authors: Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna Nuti, Lorenza Putignani, Paolo Marchetti
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Journal of Translational Medicine
Online Access:https://doi.org/10.1186/s12967-020-02231-0

Internet

https://doi.org/10.1186/s12967-020-02231-0

Similar Items